Breaking drug resistance in cancer through the development of a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.

In the Press

ApoGen Biotechnologies Expands Series A Financing to $11 Million and Enhances Leadership Team

Click Here


Accelerator Corporation Announces $7M Series A Investment in ApoGen Biotechnologies to Develop a New Class of Drugs Targeting Resistance to Cancer Therapy

Click Here

ApoGen Biotechnologies Raises $7 Million Series A

(Wall Street Journal Online)

ApoGen Biotech Lands $7M to Take On Drug Resistance in Cancer